Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Consolidated Net Income (2023 - 2026)

Compass Therapeutics' Consolidated Net Income history spans 4 years, with the latest figure at -$20.3 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 22.04% to -$20.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$75.2 million, a 28.45% decrease, with the full-year FY2025 number at -$72.8 million, down 28.63% from a year prior.
  • Consolidated Net Income hit -$20.3 million in Q1 2026 for Compass Therapeutics, down from -$18.0 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for CMPX hit a ceiling of -$7.8 million in Q1 2023 and a floor of -$21.1 million in Q2 2025.
  • Historically, Consolidated Net Income has averaged -$14.4 million across 4 years, with a median of -$13.4 million in 2023.
  • The widest YoY moves for Consolidated Net Income: up 8.54% in 2025, down 61.1% in 2025.
  • Tracing CMPX's Consolidated Net Income over 4 years: stood at -$13.4 million in 2023, then fell by 23.55% to -$16.6 million in 2024, then fell by 8.54% to -$18.0 million in 2025, then fell by 12.83% to -$20.3 million in 2026.
  • Business Quant data shows Consolidated Net Income for CMPX at -$20.3 million in Q1 2026, -$18.0 million in Q4 2025, and -$15.8 million in Q3 2025.